Get started
Author

Jennifer I. Smart

Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia
2023 · Thomas L. Holland, Sara E. Cosgrove, et al. · New England Journal of Medicine · 123
PDF
Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET)
2020 · J Scott Overcash, Charles Kim, et al. · Clinical Infectious Diseases · 72
PDF
Human Herpesvirus 8-Encoded vGPCR Activates Nuclear Factor of Activated T Cells and Collaborates with Human Immunodeficiency Virus Type 1 Tat
2003 · Shibani Pati, James S. Foulke, et al. · Journal of Virology · 69
Ceftobiprole Activity against Gram-Positive and -Negative Pathogens Collected from the United States in 2006 and 2016
2018 · Michael A. Pfaller, Robert K. Flamm, et al. · Antimicrobial Agents and Chemotherapy · 58
The LysR-Type Transcriptional Regulator QseD Alters Type Three Secretion in Enterohemorrhagic Escherichia coli and Motility in K-12 Escherichia coli
2010 · Benjamin J. Habdas, Jennifer Smart, et al. · Journal of Bacteriology · 37
Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016–2017)
2019 · Michael A. Pfaller, Robert K. Flamm, et al. · Diagnostic Microbiology and Infectious Disease · 27
A Review of Telavancin Activity in in Vitro Biofilms and Animal Models of Biofilm-Associated Infections
2015 · Cynthia Chan, Thomas C Hardin, et al. · Future Microbiology · 25
Probing the Role of Protein Surface Charge in the Activation of PrfA, the Central Regulator of Listeria monocytogenes Pathogenesis
2011 · Bobbi Xayarath, Karl W. Volz, et al. · PLoS ONE · 25
PDF
Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018
2020 · Robert K. Flamm, Leonard R. Duncan, et al. · Antimicrobial Agents and Chemotherapy · 23
A Phase 3, Randomized, Investigator-blinded Trial Comparing Ceftobiprole With a Standard-of-care Cephalosporin, With or Without Vancomycin, for the Treatment of Pneumonia in Pediatric Patients
2021 · Miroslava Bosheva, Rusudan Gujabidze, et al. · The Pediatric Infectious Disease Journal · 19
Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations
2017 · Ronald N. Jones, Robert K. Flamm, et al. · Diagnostic Microbiology and Infectious Disease · 18
PDF
Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014)
2017 · Leonard R. Duncan, Helio S. Sader, et al. · Journal of Global Antimicrobial Resistance · 17
A novel C-terminal mutation resulting in constitutive activation of the Listeria monocytogenes central virulence regulatory factor PrfA
2011 · Bobbi Xayarath, Jennifer I. Smart, et al. · Microbiology · 17
Comparative activity of ceftobiprole against coagulase-negative staphylococci from the BSAC Bacteraemia Surveillance Programme, 2013–2015
2018 · Anne Santerre Henriksen, Jennifer Smart, et al. · European Journal of Clinical Microbiology & Infectious Diseases · 16
PDF
Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011–2014)
2017 · R. E. Mendes, H. S. Sader, et al. · European Journal of Clinical Microbiology & Infectious Diseases · 15
PDF
Ceftobiprole activity against Gram-positive and Gram-negative pathogens causing bone and joint infections in the United States from 2016 to 2020
2022 · Leonard R. Duncan, Kamal A. Hamed, et al. · Diagnostic Microbiology and Infectious Disease · 9
PDF
Susceptibility to ceftobiprole of respiratory-tract pathogens collected in the United Kingdom and Ireland during 2014–2015
2018 · Anne Santerre Henriksen, Jennifer I Smart, et al. · Infection and Drug Resistance · 9
PDF
In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions
2017 · Michael A. Pfaller, Helio S. Sader, et al. · Microbial Drug Resistance · 9
PDF
Ceftobiprole activity against multidrug-resistant Staphylococcus aureus clinical isolates collected in the United States from 2016 through 2022
2025 · Helio S. Sader, Jennifer I. Smart, et al. · Antimicrobial Agents and Chemotherapy · 8
Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates
2016 · Jennifer I. Smart, Gordon Ralph Corey, et al. · Infectious Diseases and Therapy · 7
PDF
Ceftobiprole Medocaril Is an Effective Post-Exposure Treatment in the Fischer 344 Rat Model of Pneumonic Tularemia
2023 · Mark M. Hahn, Cheryl A. Triplett, et al. · Antibiotics · 6
PDF
Assessment of telavancin minimal inhibitory concentrations by revised broth microdilution method in phase 3 complicated skin and skin-structure infection clinical trial isolates
2016 · Jennifer I. Smart, G. Ralph Corey, et al. · Diagnostic Microbiology and Infectious Disease · 6
PDF
Telavancin activity tested against a collection of Staphylococcus aureus isolates causing pneumonia in hospitalized patients in the United States (2013–2014)
2016 · Leonard R. Duncan, Jennifer I. Smart, et al. · Diagnostic Microbiology and Infectious Disease · 6
PDF
Evaluation of the bactericidal activity of Telavancin against Staphylococcus aureus using revised testing guidelines
2017 · Debora Sweeney, Dean L. Shinabarger, et al. · Diagnostic Microbiology and Infectious Disease · 4
PDF
Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance
2025 · Andrew F. Shorr, Mark E. Jones, et al. · PLoS ONE · 3
PDF
Works count: 44
Citation count: 637
H-index: 15
I10-index: 15
Year
Topic
Type